ESC 2021: Late-breaking Science Video Collection

Published: 02 September 2021

Views:
5655
Likes:
7

Views:
5655
Likes:
7
Share:

Now Playing
Part 3 | Session 2 of 11
SYNTAX II Trial: 5yr Data Shows Reduction in MACE in PCI
Adrian P Banning

Up Next
8m 40s

Part 3 | Session 3 TWILIGHT-HBR: Ticagrelor Monotherapy in HBR Patients Undergoing PCI
Davide Cao
5m 21s

Part 3 | Session 4 The LAAOS III Study: Surgical AFIB Ablation Evaluation
Richard Whitlock
9m

Part 3 | Session 5 TWILIGHT-Stent: Ticagrelor Monotherapy According to Stent Type
George D Dangas
5m 43s

Part 3 | Session 6 STOPDAPT-2 ACT: 1-Month DAPT Followed by Clopidogrel Monotherapy in ACS
Hirotoshi Watanabe
5m 41s

Part 3 | Session 7 SPLENDOR: Metabolic Surgery and Risk of MACE in NASH
Ali Aminian
5m 11s

Part 3 | Session 8 RESPONSE-2: Benefits of Community-based Lifestyle Programme Were Lost After 1yr in CAD Patients
Harald Thune Jorstad
6m 9s

Part 3 | Session 9 VOYAGER PAD: Rivaroxaban in Symptomatic PAD With & Without Comorbid Diabetes
Cecilia Low Wang
5m 50s

Part 3 | Session 10 Micra CED: 2-Year Outcomes with Leadless Pacing
Jonathan Piccini
10m 53s

Part 3 | Session 11 RIPCORD 2: FFR During Angiography Did Not Improve Patient Outcomes
Nick Curzen

20m 32s

Part 4 Masterclass on The Global Burden of CV Disease in Women
Birgit Vogel, Harriette Van Spall

25m 18s

Part 1 | Session 1 View from the Thoraxcenter – What's Hot at ESC 2021 Nicolas M Van Mieghem, Joost Daemen

36m 1s

Part 1 | Session 2 View from the Thoraxcenter: ESC 21 Late-breaking Science Wrap Up Joost Daemen, Nicolas M Van Mieghem

19m 47s

Part 2 | Session 1 ESC 2021 Discussion: The EMPEROR-Preserved Trial Harriette Van Spall, Stefan Anker

15m 2s

Part 2 | Session 2 ESC 2021 Discussion: The FIGARO-DKD Trial Bertram Pitt, Harriette Van Spall

20m 8s

Part 2 | Session 3 ESC 2021 Discussion: The EMPEROR-Pooled Study Milton Packer, Harriette Van Spall

6m 33s

Part 3 | Session 1 ENVISAGE-TAVI AF: Edoxaban noninferior to warfarin for adverse events after TAVI George D Dangas

Average (ratings)

No ratings

Your rating

Overview

Our regular review series View from the Thoraxcenter hosted by Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) provide a concise analysis of the late-breaking science results and spotlight impactful data.

For a deeper dive into key clinical trial data, Dr Harriette Van Spall (McMaster University, Hamilton, CA) interviewed principal investigators on their studies, learnings, and applicability to clinical practice in her regular Late-Breaker Discussion Series.

Short, accessible Expert Interviews were conducted with select faculty focusing on the results, applicability, and impact on future research.

More from this programme

Part 1

View from the Thoraxcenter

In the latest episode View from the Thoraxcenter, Professor Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) offer their concise analysis of the hot line and late-breaking trials that will be presented at ESC Congress 2021. What presentations should we look at for this weekend? Get your update on the importance of trials such as GUIDE-HF, MASTER DAPT, TOMAHAWK and many more delivered by our world-class experts, Professor Van Mieghem and Dr Joost Daemen.

2 sessions
View from the Thoraxcenter – What's Hot at ESC 2021	Watch now
View from the Thoraxcenter: ESC 21 Late-breaking Science Wrap Up	Watch now

Part 2

Late-breaker Discussion Series

Host, Dr Harriette Van Spall interviews the late-breaker and hot line presenters of ESC Congress 2021.

3 sessions
ESC 2021 Discussion: The EMPEROR-Preserved Trial	Watch now
ESC 2021 Discussion: The FIGARO-DKD Trial	Watch now
ESC 2021 Discussion: The EMPEROR-Pooled Study	Watch now

Part 3

Expert Interviews

Short, accessible Expert Interviews were conducted with select faculty focusing on the results, applicability, and impact on future research.

11 sessions
ENVISAGE-TAVI AF: Edoxaban noninferior to warfarin for adverse events after TAVI	Watch now
SYNTAX II Trial: 5yr Data Shows Reduction in MACE in PCI	Watch now
TWILIGHT-HBR: Ticagrelor Monotherapy in HBR Patients Undergoing PCI	Watch now
The LAAOS III Study: Surgical AFIB Ablation Evaluation	Watch now
TWILIGHT-Stent: Ticagrelor Monotherapy According to Stent Type	Watch now
STOPDAPT-2 ACT: 1-Month DAPT Followed by Clopidogrel Monotherapy in ACS	Watch now
SPLENDOR: Metabolic Surgery and Risk of MACE in NASH	Watch now
RESPONSE-2: Benefits of Community-based Lifestyle Programme Were Lost After 1yr in CAD Patients	Watch now
VOYAGER PAD: Rivaroxaban in Symptomatic PAD With & Without Comorbid Diabetes	Watch now
Micra CED: 2-Year Outcomes with Leadless Pacing	Watch now
RIPCORD 2: FFR During Angiography Did Not Improve Patient Outcomes	Watch now

Part 4

Masterclass with Dr Harriette Van Spall & Dr Birgit Vogel

In the ESC Congress 2021 episode of the Masterclass video series, host, Dr Harriette Van Spall (McMaster University, CA) meets with Dr Birgit Vogel (Icahn School of Medicine at Mount Sinai, US), one of the commissioners and first author of the "The Lancet women and cardiovascular disease Commission: reducing the global burden by 2030" report.

1 session
Masterclass on The Global Burden of CV Disease in Women	Watch now

Faculty Biographies

Adrian P Banning

Consultant Cardiologist

Prof Adrian Banning is a Consultant Cardiologist, specialising in percutaneous coronary intervention. He works as a Consultant in interventional and general cardiology and is one of the founder members of the Oxford Private Heart and Lung Centre at Nuffield Health Oxford at The Manor Hospital.

He is recognised as one of the UK’s top interventional cardiologists and until recently he was President of the British Cardiac Intervention Society. He performs more than 250 coronary intervention procedures every year and he is an expert in TAVI –implantation of a new aortic valve through a keyhole incision and performs >150 of these TAVI procedures each year.

Prof Banning is pioneering research in his field and lectures nationally and internationally. He has authored several books on coronary intervention and has more than 300 PubMed listed scientific papers to his name.

View full profile